Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy InflaRx N-V stock

Learn how to easily invest in InflaRx N-V stock.

InflaRx N.V. is a biotechnology business based in the US. InflaRx N-V shares (IFRX) are listed on the NASDAQ and all prices are listed in US Dollars. InflaRx N-V employs 55 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in InflaRx N-V

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – IFRX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

InflaRx N-V stock price (NASDAQ: IFRX)

Use our graph to track the performance of IFRX stocks over time.

InflaRx N-V shares at a glance

Information last updated 2022-06-25.
Latest market close$1.52
52-week range$0.78 - $5.69
50-day moving average $1.49
200-day moving average $2.91
Wall St. target price$5.06
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.27

Buy InflaRx N-V shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
$10
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$1
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Axos Bank Self Directed Investing
Stocks
$0
$1,000
$150
when you open an account and deposit at least $1500.
Vanguard Personal Advisor
Stocks, Mutual funds, ETFs
$0
$0
N/A
Financial advice powered by relationships, not commissions.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy InflaRx N-V stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

InflaRx N-V price performance over time

Historical closes compared with the close of $1.52 from 2022-06-28

1 week (2022-06-22) 25.62%
1 month (2022-05-27) 3.40%
3 months (2022-03-29) -34.20%
6 months (2021-12-29) -64.65%
1 year (2021-06-29) -48.82%
2 years (2020-06-29) -68.53%
3 years (2019-06-28) 3.16
5 years (2017-06-25) N/A

InflaRx N-V financials

Gross profit TTM $0
Return on assets TTM -26%
Return on equity TTM -45.74%
Profit margin 0%
Book value $2.15
Market capitalisation $34.5 million

TTM: trailing 12 months

InflaRx N-V share dividends

We're not expecting InflaRx N-V to pay a dividend over the next 12 months.

InflaRx N-V share price volatility

Over the last 12 months, InflaRx N-V's shares have ranged in value from as little as $0.776 up to $5.686. A popular way to gauge a stock's volatility is its "beta".

IFRX.US volatility(beta: 0.82)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while InflaRx N-V's is 0.8214. This would suggest that InflaRx N-V's shares are less volatile than average (for this exchange).

InflaRx N-V overview

InflaRx N. V. , a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co.

Frequently asked questions

What percentage of InflaRx N-V is owned by insiders or institutions?
Currently 14.905% of InflaRx N-V shares are held by insiders and 15.157% by institutions.
How many people work for InflaRx N-V?
Latest data suggests 55 work at InflaRx N-V.
When does the fiscal year end for InflaRx N-V?
InflaRx N-V's fiscal year ends in December.
Where is InflaRx N-V based?
InflaRx N-V's address is: Winzerlaer Str. 2, Jena, Germany, 07745
What is InflaRx N-V's ISIN number?
InflaRx N-V's international securities identification number is: NL0012661870
What is InflaRx N-V's CUSIP number?
InflaRx N-V's Committee on Uniform Securities Identification Procedures number is: N44821101

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site